Tengion, Inc. (OTCMKTS:TNGN) on Mar. 3 issued notices to the holders (the “2012 Investors”) of senior secured notes issued on October 2, 2012 and to the holders (the “2013 Investors” and together with the 2012 Investors, the “Investors” and each, an “Investor”) of senior secured notes issued on June 28, 2013 stating that the Company plans to issue shares of common stock, $0.001 par value per share, or warrants to purchase Common Stock for nominal consideration, to the 2012 Investors in satisfaction of $354,071.43 in interest payments and to the 2013 Investors in satisfaction of $438,033.55, each due on Apr. 1, 2014. Tengion, Inc. (OTCMKTS:TNGN) stock performance was 16.38% in last session and finished the day at $0.270. Traded volume was 3.64 million shares in the last session and the average volume of the stock remained 473,520.00 shares. The beta of the stock remained 2.58. Tengion, Inc. (OTCMKTS:TNGN) insider ownership is 41.46%.

Alseres Pharmaceuticals, Inc. (OTCMKTS:ALSE) is a development-stage company. The Company is a biotechnology company focused on the development of diagnostic and therapeutic products primarily for disorders in the central nervous system, or CNS. Alseres Pharmaceuticals, Inc. (OTCMKTS:ALSE) rose 100.00% to $0.0500 yesterday on volume of 178,647.00 shares. The intra-day range of the stock was $0.04 – $0.05. Alseres Pharmaceuticals, Inc. (OTCMKTS:ALSE) has a market capitalization of 1.15 million.

Fate Therapeutics, Inc. (NASDAQ:FATE) announced that it has enrolled the first patient in its phase II study (PUMA − P rohema in UM bilical cord blood transplant in A dults) on Prohema. Fate Therapeutics Inc. (NASDAQ:FATE)’s stock on March 14, 2014 reported a higher of 27.14% to the closing price of $11.15. Its fifty two weeks range is $4.30 – $12.81. The total market capitalization recorded 14.08 million. The overall volume in the last trading session was 295,227.00 shares. In its share capital, Fate Therapeutics Inc. (NASDAQ:FATE) has 1.26 million outstanding shares.

Synthetic Biologics, Inc. (NYSEMKT:SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,658,627 entitled, Pregnancy Hormone Combination for Treatment of Autoimmune Diseases, to the Regents of the University of California (UCLA). On Friday, shares of Synthetic Biologics Inc. (NYSEMKT:SYN) advanced 6.10% to close the day at $3.13. Company return on investment (ROI) is – and its monthly performance is recorded as 63.02%. Synthetic Biologics Inc. (NYSEMKT:SYN) quarterly revenue growth is 146.46%.